JP2024511853A5 - - Google Patents

Info

Publication number
JP2024511853A5
JP2024511853A5 JP2023560403A JP2023560403A JP2024511853A5 JP 2024511853 A5 JP2024511853 A5 JP 2024511853A5 JP 2023560403 A JP2023560403 A JP 2023560403A JP 2023560403 A JP2023560403 A JP 2023560403A JP 2024511853 A5 JP2024511853 A5 JP 2024511853A5
Authority
JP
Japan
Prior art keywords
seq
domain
queel
amino acid
gfral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023560403A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024511853A (ja
Filing date
Publication date
Priority claimed from GBGB2104556.2A external-priority patent/GB202104556D0/en
Priority claimed from GBGB2107331.7A external-priority patent/GB202107331D0/en
Priority claimed from GBGB2108170.8A external-priority patent/GB202108170D0/en
Application filed filed Critical
Priority claimed from PCT/EP2022/058669 external-priority patent/WO2022207846A1/en
Publication of JP2024511853A publication Critical patent/JP2024511853A/ja
Publication of JP2024511853A5 publication Critical patent/JP2024511853A5/ja
Pending legal-status Critical Current

Links

JP2023560403A 2021-03-31 2022-03-31 Gdf15シグナル伝達の治療的阻害剤 Pending JP2024511853A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB2104556.2 2021-03-31
GBGB2104556.2A GB202104556D0 (en) 2021-03-31 2021-03-31 Therapeutic inhibitors of GDF15 signalling
GBGB2107331.7A GB202107331D0 (en) 2021-05-21 2021-05-21 Therapeutic inhibitors of GDF15 signalling
GB2107331.7 2021-05-21
GB2108170.8 2021-06-08
GBGB2108170.8A GB202108170D0 (en) 2021-06-08 2021-06-08 Theraputic inhibitors of GDF15 Signalling
PCT/EP2022/058669 WO2022207846A1 (en) 2021-03-31 2022-03-31 Therapeutic inhibitors of gdf15 signalling

Publications (2)

Publication Number Publication Date
JP2024511853A JP2024511853A (ja) 2024-03-15
JP2024511853A5 true JP2024511853A5 (https=) 2025-04-07

Family

ID=81580347

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023560403A Pending JP2024511853A (ja) 2021-03-31 2022-03-31 Gdf15シグナル伝達の治療的阻害剤

Country Status (11)

Country Link
US (1) US20240182585A1 (https=)
EP (1) EP4314071A1 (https=)
JP (1) JP2024511853A (https=)
KR (1) KR20230165285A (https=)
AU (1) AU2022251923A1 (https=)
BR (1) BR112023020152A2 (https=)
CA (1) CA3215737A1 (https=)
CO (1) CO2023013791A2 (https=)
IL (1) IL307382A (https=)
MX (1) MX2023011655A (https=)
WO (1) WO2022207846A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY194669A (en) 2016-03-31 2022-12-12 Ngm Biopharmaceuticals Inc Binding Proteins and Methods of use Thereof
IT202300006387A1 (it) * 2023-03-31 2024-10-01 Univ Degli Studi Roma La Sapienza Inibitore del recettore gfral per uso nel trattamento della sclerosi laterale amiotrofica

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US7083784B2 (en) 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
US20050266425A1 (en) 2003-12-31 2005-12-01 Vaccinex, Inc. Methods for producing and identifying multispecific antibodies
EP2441466B1 (en) 2004-04-13 2014-07-23 St Vincent's Hospital Sydney Limited MIC-1 inhibiting agent
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
US8901129B2 (en) 2009-12-11 2014-12-02 Genecode As Methods of facilitating neural cell survival using GDNF family ligand (GFL) mimetics or RET signaling pathway activators
WO2013012648A1 (en) 2011-07-15 2013-01-24 Emory University Gdf15 in diagnostic and therapeutic applications
CN102321173B (zh) 2011-08-12 2013-04-03 中国医学科学院肿瘤研究所 人源化巨噬细胞抑制因子1单克隆抗体及其应用
RS59045B1 (sr) 2012-09-26 2019-08-30 Univ Wuerzburg J Maximilians Monoklonalna antitela za faktor 15 rasta i diferencijacije (gdf-15)
ES2791183T3 (es) 2012-12-21 2020-11-03 Aveo Pharmaceuticals Inc Anticuerpos anti-GDF15
RS59700B1 (sr) 2014-03-26 2020-01-31 Univ Wuerzburg J Maximilians Monoklonalna antitela za faktor 15 (gdf-15) rasta i diferencijacije, i njihove upotrebe u lečenju kancerske kaheksije i kancera
PL3197493T3 (pl) 2014-09-25 2021-08-23 Aveo Pharmaceuticals Inc. Sposoby odwracania kacheksji i przedłużania przeżycia obejmujące podanie modulatora gdf15 i środka przeciwnowotworowego
CN108463246B (zh) 2015-10-02 2025-02-28 尤利乌斯·马克西米利安维尔茨堡大学 使用人生长分化因子15(gdf-15)抑制剂和免疫检查点阻断剂的联合治疗
WO2017121865A1 (en) 2016-01-15 2017-07-20 Novo Nordisk A/S Mic-1 receptor and uses thereof
CN108697795A (zh) * 2016-02-29 2018-10-23 伊莱利利公司 Gfral受体疗法
US20170299608A1 (en) 2016-03-04 2017-10-19 Ngm Biopharmaceuticals, Inc. Compositions and methods for modulating body weight
MY194669A (en) 2016-03-31 2022-12-12 Ngm Biopharmaceuticals Inc Binding Proteins and Methods of use Thereof
WO2017189724A1 (en) 2016-04-27 2017-11-02 Novartis Ag Antibodies against growth differentiation factor 15 and uses thereof

Similar Documents

Publication Publication Date Title
JP7682335B2 (ja) オンコスタチンm受容体抗原結合タンパク質
JP7665098B2 (ja) 多重特異性抗体およびその使用
JP2018521691A5 (https=)
US12194095B2 (en) Combinations and uses thereof
BR112021008288A2 (pt) composição farmacêutica de proteína de fusão do receptor tgf-ss e uso da mesma
RU2018106364A (ru) Антитела против рецептора tfr и их применение при лечении пролиферативных и воспалительных расстройств
JP2016538876A5 (https=)
KR20160062167A (ko) 죽상경화증의 치료를 위한 세마포린-4d 결합 분자의 용도
RU2014139552A (ru) Человеческие антитела к токсинам clostridium difficile
JP2015503909A5 (https=)
KR102500868B1 (ko) 항-cd19 항체 및 bcl-2 억제제의 조합 및 이의 용도
WO2012098238A1 (en) Combination therapies and methods using anti-cd3 modulating agents and anti-il-6 antagonists
KR20160135835A (ko) 인간 카나비노이드 1(cb1) 수용체 결합 항체
JP2020522280A5 (https=)
JP2024511853A5 (https=)
JP2022544050A5 (https=)
TW202108631A (zh) 一種抗cd47抗原結合蛋白及其應用
JP2022527542A5 (https=)
JP2024505195A5 (https=)
JP2024502670A5 (https=)
JP7668943B2 (ja) 多重特異性抗体およびその使用
CN114316046B (zh) 一种稳定的抗体组合物
JP2025036273A (ja) 多重特異性抗体およびその使用
JP2022537142A5 (https=)
JP2025539796A (ja) Lag-3およびpd-1/lag-3抗体